Citations

Mayo Clinic

Clear

448 citation(s) found for "JUNG, T".

Melittin Inhibits TGF-β-Induced Pro-Fibrotic Gene Expression Through the Suppression of the TGFβRII-Smad, ERK1/2 and JNK-Mediated Signaling Pathway
Park, Suhyun , Cho, Hyun-Ji , Shin, Jae-Moon, Kang, Jeong Han , Park, Kwan‐Kyu , Choe, Jung‐Yoon , Park, Yoon-Yub , Han, Sang‐Mi , Moon, Sung‐Kwon , Chang, Young‐Chae , Jeong, Yun‐Jeong , Bae, Young‐Seuk , Kim, Wun‐Jae , Choi, Yung Hyun

The American Journal of Chinese Medicine | September 2, 2014 | Volume: 42 | Issue: 05 | Pages: 1139-1152

10.1142/s0192415x14500712 | PMID 25178280 Get It

Renal fibrosis is characterized by the excessive accumulation of extracellular matrix (ECM) proteins such as type I collagen, fibronectin, and by the increased expression of PAI-1. This study evaluated the anti-fibrotic effect of bee venom and its major compounds (melittin and apamin) on TGF-β-induced pro-fibrotic gene expression. Bee venom and melittin significantly suppressed type I collagen, fibronectin, and PAI-1 protein expression in the TGF-β-treated kidney fibroblast. However, apamin only inhibited the expression of fibronectin and type I collagen. These results indicated that the inhibitory effects of bee venom on TGF-β-induced pro-fibrotic gene expression are caused by melittin. Moreover, we attempted to elucidate mechanisms underlying the anti-fibrotic effect of melittin. Melittin dramatically inhibited the phosphorylation of TGFβRII and Smad2/3. Also, melittin inhibited the phosphorylation of ERK1/2 and JNK, but not the phosphorylation of PI3K, Akt, and p38. These results suggested that melittin inhibits TGF-β-induced pro-fibrotic genes expression through the suppression of TGFβR-Smad2/3, ERK1/2, and JNK phosphorylation, and melittin can be used as a clinical drug for the treatment of fibrosis associated with renal diseases.
Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces
Simonetto, Douglas A. , Yang, Hui‐yin, Yin, Meng , Assuncao, Thiago M. de , Kwon, Jung Hee, Hilscher, Moira , Pan, Shuchong, Yang, Liu , Bi, Yan , Cao, Sheng , Simari, Robert D., Kamath, Patrick S. , Shah, Vijay H. , Yang, Hui-yin, Beyder, Arthur , Ehman, Richard L. , Yin, Meng , Simonetto, Douglas A

Hepatology | August 20, 2014 | Volume: 61 | Issue: 2 | Pages: 648-659

10.1002/hep.27387 | PMID 25142214 Get It

Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; however, the mechanisms involved in this process are not well understood. We developed a murine experimental model of congestive hepatopathy through partial ligation of the inferior vena cava (pIVCL). C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22α‐TFPI) were subjected to pIVCL or sham. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, real‐time polymerase chain reaction, and western blot assays. Hepatic fibrosis and portal pressure were significantly increased after pIVCL concurrent with hepatic stellate cell (HSC) activation. Liver stiffness, as assessed by magnetic resonance elastography, correlated with portal pressure and preceded fibrosis in our model. Hepatic sinusoidal thrombosis as evidenced by fibrin deposition was demonstrated both in mice after pIVCL as well as in humans with congestive hepatopathy. Warfarin treatment and TFPI overexpression both had a protective effect on fibrosis development and HSC activation after pIVCL. In vitro studies show that congestion stimulates HSC fibronectin (FN) fibril assembly through direct effects of thrombi as well as by virtue of mechanical strain. Pretreatment with either Mab13 or Cytochalasin‐D, to inhibit β‐integrin or actin polymerization, respectively, significantly reduced fibrin and stretch‐induced FN fibril assembly. Conclusion : Chronic hepatic congestion leads to sinusoidal thrombosis and strain, which in turn promote hepatic fibrosis. These studies mechanistically link congestive hepatopathy to hepatic fibrosis. (H epatology 2015;61:648‐659)
Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice
Jung, Jaehoon , Kim, Hwajin , Heo, Rok Won, Yi, Chin‐ok, Jeon, Byeong Tak, Kim, Won–Ho , Hahm, Jong Ryeal , Kim, Seok Chan , Lee, Jung Eun , Roh, Gu Seob

The Korean Journal of Physiology & Pharmacology | August 20, 2014 | Volume: 18 | Issue: 4 | Pages: 333

10.4196/kjpp.2014.18.4.333 | PMID 25177166 Get It

Abstract 2021: Characterization of myeloma tumors from a multi-ethnic cohort using cytogenetics and genomic analysis.
Baker, Angela , Jacobus, Susana, Jung, Sungwon , Therneau, Terry, Wier, Scott A. Van, Ahmann, Gregory , Levy, Joan, Henderson, Kim, Vesole, David H., Jelinek, Dianne F., Carpten, John D. , Braggio, Esteban , Larson, Dirk R. , Dispenzieri, Angela , Perkins, Louise M. , Kim, Seungchan , Henderson, Kimberly J., Rajkumar, S. Vincent , Fonseca, Rafaël

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 2021-2021

10.1158/1538-7445.am2013-2021 Get It

Abstract The plasma cell malignancy Multiple Myeloma (MM) is a rare but deadly form of cancer with 5 year survival rates of ∼30%. Epidemiological studies have suggested that MM exacts an especially heavy burden on African American (AA) patients. We examined a multi-ethnic cohort of MM tumors to assess potential differences in the frequency of molecular events in tumors derived from either African American (AA) or European American (EA) patients. The frequency of 14q32 translocation breakpoints at the IgH locus was compared among a series of data from 115 AA MM patients from three studies and EA MM from the Eastern Cooperative Oncology Group (ECOG). In addition, we analyzed matching genome-wide copy number and transcriptional data among 45 AA MM tumors and 196 EA MM tumors to determine differences in the frequency of molecular events in tumors from these populations. No differences were found for specific translocation subtypes; however, we detected a statistically significant difference in the overall frequency of IgH translocations between the two groups, which occurred more frequently in EA patients (52% vs. 40%; p = 0.032). When assessing genomic copy number events previously shown to be associated with poor outcome in MM, frequencies of alterations were not significant after correcting for multiple testing. Furthermore, there was not a significant difference in the association of high-risk disease using expression profiling. Our study represents the first comprehensive assessment of the frequency and distribution of molecular alterations in MM tumors from both AA and EA patients and could help shed light on possible biological features associated with population differences in incidence and outcome in MM. Citation Format: Angela S. Baker, Esteban Braggio, Susana Jacobus, Sungwon Jung, Dirk Larson, Terry Therneau, Angela Dispenzieri, Scott A. Van Wier, Gregory Ahmann, Joan Levy, Louise Perkins, Seungchan Kim, Kim Henderson, David Vesole, S. Vincent Rajkumar, Dianne F. Jelinek, John Carpten, Rafael Fonseca. Characterization of myeloma tumors from a multi-ethnic cohort using cytogenetics and genomic analysis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2021. doi:10.1158/1538-7445.AM2013-2021
Abstract B37: Proteomic and metabolomic analyses of glioblastoma using mass spectrometry.
Ha, Soo Jung, Showalter, Gordon, Cai, Shanbao , Wang, Haiyan , Liu, Wei Michael, Springer, John, Pollok, Karen E. , Rickus, Jenna L. , Sarkaria, Jann N. , Adamec, Jiří , Clase, Kari Lynn

Molecular Cancer Therapeutics | August 14, 2014 | Volume: 12 | Issue: 11_Supplement | Pages: B37-B37

10.1158/1535-7163.targ-13-b37 Get It

Abstract Glioblastoma (GBM) is the most common and malignant form of primary brain tumor. Average survival rate of GBM is 12-15 months from diagnosis. Due to its highly invasive nature, current treatment options have not been able to improve the survival rate in past 20 years. In order to discover GBM therapeutic targets, omics technologies have been widely used in order to identify potential biomarkers. Identification of cancer biomarkers for diagnosis and prognosis continues to evolve as clinical specimen pipelines and technologies are optimized. This research study focused on investigating proteins, metabolites and lipids biomarkers and patterns of human GBM xenografts employing mass spectrometry. Human tumor cell lines GBM 10 and GBM 43 were injected in the right cerebral hemisphere and flank sites in NOD/SCID mice (n = 10 mice per group). After harvesting brain and flank tumors and control brain from mouse models, protein, metabolites, and lipids of tumor samples were collected through one simple extraction procedure, which may solve sample preparation difficulties in omics studies, developed by Dr. Jiri Adamec. These samples were analyzed by reverse phase high performance liquid chromatography - Fourier transform ion cyclotron resonance mass spectrometry (LC-FTMS). FTMS analyzers have the highest resolving power of all MS instruments, which is ideal for complex mixtures such as GBM tissue. Spectra obtained from the FTMS analysis were analyzed using Student t-tests to detect significant differences in tissue profiles at a level of p = 0.05. Compounds below this threshold were identified through a database using the m/z ratio. Lipidomic analysis indicated the possible up and down-regulation of several lipids classes in GBM tissue connected to metabolic pathways, tumor proliferation and immunodepression, such as glycerophospholipids, both up- and down-regulated (e.g. PC38:4 or PG 35:2, respectively), and down-regulated glycosphingolipids (Galβ1-3GlcNAcβ1-3Galβ1-4Glc-Cer, Galβ1-4GlcNAcβ1-3Galβ1-4Glc-Cer), and triglycerides (TG 55:9, 53:4,52:8). We expect that integrated studies of proteomics, metabolomics, and lipidomics increase the confidence of identification of potential biomarkers. Accompanying these studies is a collaborative effort to improve the effectiveness and efficiency of computational pipelines that are imperative to the analytics, visualization, identification, and interpretation of the omics data. Only by carefully integrating the computational pipelines can we successfully perform the types of integrative studies needed to advance the identification of cancer biomarkers for diagnosis and prognosis, and our integrative studies serve as a case study for our pipeline advancement efforts. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B37. Citation Format: Soo Jung Ha, Gordon Showalter, Jenna Rickus, Shanbao Cai, Haiyan Wang, Wei Michael Liu, Jann N. Sarkaria, John Springer, Jiri Adamec, Karen E. Pollok, Kari L. Clase. Proteomic and metabolomic analyses of glioblastoma using mass spectrometry. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B37.
Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
Mansour, Ahmad M. , Arévalo, J. Fernando , Kahtani, Eman Al, Zegarra, Hernando, Abboud, Emad B. , Anand, Rajiv, Ahmadieh, Hamid , Mirza, Salman, Tuncer, Samuray , Návea, Amparo , Mataix, J. , Ascaso, Francisco J., Pulido, José S. , Guthoff, Rainer , Goebel, Winfried, Banker, Alay , Gentile, Ronald C., Martinez, Isabel Alonso, Morris, Rodney J, Panday, Neeraj, Min, Park Jung, Mercé, Emilie, Lai, Timothy Y. Y. , Massoud, Vicky, Ghazi, Nicola G. , Abboud, Emad , Sisk, Robert A. , Roh, Young‐Jung , Martínez, Isabel Alonso, Massoud, Vicky A., Arevalo, Jose Fernando

Journal of Ophthalmology | July 23, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-8

10.1155/2014/210458 | PMID 25147732 Get It

We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n=15;P=0.001), 105.3 microns at 1 year (n=10;P=0.03), and 157.6 microns at 2 years (n=7;P=0.08). BCVA improved by 3.3 lines at 6 months after therapy (n=26;P<0.001), 2.8 lines (n=20;P=0.01) at 1 year, and 3.1 lines (n=13;P=0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.
Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome
Onozawa, Masahiro , Kim, Yoo Jung , Goldberg, Liat, Bergsagel, P. Leif , Kuehl, W. Michael, Aplan, Peter D. , Bergsagel, P. Leif , Zhang, Zhenhua , Varga, Tamás

Proceedings of the National Academy of Sciences | May 13, 2014 | Volume: 111 | Issue: 21 | Pages: 7729-7734

10.1073/pnas.1321889111 | PMID 24821809 Get It

Significance We show that DNA double-strand breaks (DSBs) can be repaired by insertion of 50- to 1,000-bp sequences termed “templated-sequence insertions” (TSIs) derived from distant regions of the genome. Additional experiments indicate that the source of template for repair was primarily nuclear RNA. This mode of DNA-DSB repair by insertion is not restricted to experimentally produced breaks but also occurs at the site of spontaneous DNA DSBs in human cells. These TSIs are polymorphic in the human genome, suggesting that some TSIs occur in germ cells or embryos. Recognition of these TSIs is important in interpreting structural variations in short-read sequencing studies and provides additional polymorphic markers for population and evolution studies. This error-prone form of DNA repair may play a role in genetic diseases.
Randomized Phase II Clinical Trials
Sargent, Daniel J. , Jung, Sin‐Ho , Sargent, Daniel J

Journal of Biopharmaceutical Statistics | April 3, 2014 | Volume: 24 | Issue: 4 | Pages: 802-816

10.1080/10543406.2014.901343 | PMID 24697589 Get It

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
Investigators, The Parkinson Study Group QE3, Beal, M. Flint, Oakes, David , Shoulson, Ira , Henchcliffe, Claire , Galpern, Wendy R., Haas, Richard , Juncos, Jorge L., Nutt, John G. , Voss, Tiffini, Ravina, Bernard, Shults, Clifford M., Helles, Karen, Snively, Victoria, Lew, Mark, Griebner, Brian, Watts, Arthur, Gao, Shan , Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie , Sia, Cherissa, Jog, Mandar , Sultana, Munira , Kurlan, Roger, Richard, Irene Hegeman, Deeley, Cheryl, Waters, Cheryl , Figueroa, Angel, Arkun, Ani, Brodsky, Matthew , Ondo, William G. , Hunter, Christine , Jimenez‐Shahed, Joohi , Palao, Alicia, Miyasaki, Janis M. , So, Julie , Tetrud, James W., Reys, Liza, Singer, Carlos , Blenke, Anita, Russell, David , Cotto, Candace, Lannon, Margaret C., Drasby, Edward, Kumar, Rajeev , Subramanian, Thyagarajan , Ford, Donna Stuppy, Grimes, David A. , Côté, Diane , Conway, Jennifer, Siderowf, Andrew , Evatt, Marian L., Sommerfeld, Barbara, Lieberman, Abraham, Okun, Michael S. , Rodriguez, Ramon L. , Merritt, Stacy, Swartz, Camille, Martin, W. R. Wayne , King, Pamela, Stover, Natividad , Guthrie, Stephanie, Watts, Ray L., Fernandez, Hubert H. , Winters, Adrienna, Dawson, Ted M. , Dunlop, Becky, Feigin, Andrew, Shannon, Barbara , Nirenberg, Melissa J. , Ogg, Mattson , Ellias, Samuel A., Thomas, Cathi-Ann, Frei, Karen , Bódis-Wollner, Iván , Glazman, Sofya, Mayer, Thomas A. , Hauser, Robert A. , Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Farrow, Buff, Prakash, Rajan , Litvan, Irene , Robinson, Annette, Sahay, Alok , Gartner, Maureen, Markind, Samuel, Pelikan, Melisa, Hartlein, Johanna M, Molho, Eric , Evans, Sharon, Duffy, Amy, Lind, Marlene, Elmer, Lawrence , Davis, Kathy, Spears, Julia, Leehey, Maureen A. , Hermanowicz, Neal , Niswonger, Shari, Shill, Holly A. , Obradov, Sanja, Rajput, Alex, Cowper, Marilyn, Lessig, Stephanie, Fontaine, Deborah, Zadikoff, Cindy , Williams, Karen, Blindauer, Karen, Bergholte, Jo, Propsom, Clara Schindler, Stacy, Mark, Field, Joanne, Mihaila, Dragos, Chilton, Mark, Uc, Ergun Y., Sieren, Jeri, Simon, David K. , Kraics, Lauren, Silver, Althea, Boyd, James T. , Hamill, Robert W., Ingvoldstad, Christopher T., Young, Jennifer , Thomas, Karen, Kostyk, Sandra K. , Wojcieszek, Joanne, Pfeiffer, Ronald F. , Panisset, Michel , Beland, Monica, Reich, Stephen G. , Cines, Michelle, Zappala, Nancy, Rivest, J., Zweig, Richard M., Lumina, L. Pepper, Hilliard, Colette Lynn, Grill, Stephen , Kellermann, Marye, Tuite, Paul , Rolandelli, Susan, Kang, Un Jung , Young, Joan, Rao, Jayaraman, Cook, Maureen, Severt, Lawrence, Boyar, Karyn, Scott, Ingrid U. , Investigators, The Parkinson Study Group QE3, Beal, M. Flint , Agarwal, Pinky , Cole, Linda C. , Smith, Katharine , Friedman, Joseph H. , Zhang, Lin , Ahmed, Anwar E. , Mari, Zoltan K. , Pahwa, Rajesh , Sethi, Kapil D. , Hinson, Vanessa K. , Perlmutter, Joel S. , Adler, Charles H. , Wilson, Stephanie M. G. , Song, David , Williams, Karen, Uc, Ergun Y., Okun, Michael S , Litvan, Irene , Hauser, Robert A , Jimenez-Shahed, Joohi

JAMA Neurology | March 25, 2014 | Volume: 71 | Issue: 5 | Pages: 543

10.1001/jamaneurol.2014.131 | PMID 24664227 Get It

Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-δ gene
d’Uscio, Livius V. , He, Tongrong , Santhanam, Anantha Vijay R., Tai, Li-Jung, Evans, Ronald M. , Katušić, Zvonimir S. , Evans, Ronald M

American Journal of Physiology-Heart and Circulatory Physiology | February 1, 2014 | Volume: 306 | Issue: 7 | Pages: H1001-H1010

10.1152/ajpheart.00761.2013 | PMID 24486511 Get It

Peroxisome proliferator-activated receptor (PPAR)-δ is a nuclear hormone receptor that is mainly involved in lipid metabolism. Recent studies have suggested that PPAR-δ agonists exert vascular protective effects. The present study was designed to characterize vascular function in mice with genetic inactivation of PPAR-δ in the endothelium. Mice with vascular endothelial cell-specific deletion of the PPAR-δ gene (ePPARδ−/− mice) were generated using loxP/Cre technology. ePPARδ−/− mice were normotensive and did not display any sign of metabolic syndrome. Endothelium-dependent relaxations to ACh and endothelium-independent relaxations to the nitric oxide (NO) donor diethylammonium ( Z)-1-( N, N-diethylamino)diazen-1-ium-1,2-diolate were both significantly impaired in the aorta and carotid arteries of ePPARδ−/− mice ( P < 0.05). In ePPARδ−/− mouse aortas, phosphorylation of endothelial NO synthase at Ser1177 was significantly decreased ( P < 0.05). However, basal levels of cGMP were unexpectedly increased ( P < 0.05). Enzymatic activity of GTP-cyclohydrolase I and tetrahydrobiopterin levels were also enhanced in ePPARδ−/− mice ( P < 0.05). Most notably, endothelium-specific deletion of the PPAR-δ gene significantly decreased protein expressions of catalase and glutathione peroxidase 1 and resulted in increased levels of H2O2 in the aorta ( P < 0.05). In contrast, superoxide anion production was unaltered. Moreover, treatment with catalase prevented the endothelial dysfunction and elevation of cGMP detected in aortas of ePPARδ−/− mice. The findings suggest that increased levels of cGMP caused by H2O2 impair vasodilator reactivity to endogenous and exogenous NO. We speculate that chronic elevation of H2O2 predisposes PPAR-δ-deficient arteries to oxidative stress and vascular dysfunction.